Impact of Renal Function on Anti-factor Xa Activity Concentrations with Edoxaban Use in Patients with Non-valvular Atrial Fibrillation

Comparison of Anti-factor Xa Activity Among Three Different Factor Xa Inhibitors in Non-valvular Atrial Fibrillation Patients with Renal Impairment

(2020) Akihiro Tobe et al.   CLINICAL DRUG INVESTIGATION

Edoxaban plasma levels in patients with non-valvular atrial fibrillation: Inter and intra-individual variability, correlation with coagulation screening test and renal function

(2019) Sophie Testa et al.   THROMBOSIS RESEARCH

Testing and monitoring direct oral anticoagulants

(2018) Jean M. Connors   BLOOD

Impact of Renal Function on Outcomes With Edoxaban in Real-World Patients With Atrial Fibrillation

(2018) Hee Tae Yu et al.   STROKE

Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial

(2018) Tze-Fan Chao et al.   EUROPEAN HEART JOURNAL

Monitoring of anti-Xa activity and factors related to bleeding events: A study in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban

(2017) Teruhiro Sakaguchi et al.   Journal of Cardiology

Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 TrialClinical Perspective

(2016) Erin A. Bohula et al.   CIRCULATION

Distribution of Anti-Factor Xa Activity in Patients on Edoxaban Therapy for Non-Valvular Atrial Fibrillation

(2016) Hiroyuki Osanai et al.   CIRCULATION JOURNAL

Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF

(2016) Kevin E. Chan et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Potential Effect of Substituting Estimated Glomerular Filtration Rate for Estimated Creatinine Clearance for Dosing of Direct Oral Anticoagulants

(2016) Janice B. Schwartz   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Measurement of Anti-Factor Xa Activity in Patients on Apixaban for Non-Valvular Atrial Fibrillation

(2015) Hiroyuki Osanai et al.   CIRCULATION JOURNAL

Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation

(2015) Hein Heidbuchel et al.   EUROPACE

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial

(2015) Christian T Ruff et al.   LANCET

Edoxaban: a focused review of its clinical pharmacology

(2014) G. Y. H. Lip et al.   EUROPEAN HEART JOURNAL

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

(2013) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation

(2010) Stuart Connolly et al.   THROMBOSIS AND HAEMOSTASIS

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE